Dan Hazen is the Controller at Priovant Therapeutics. He has over 13 years of financial and accounting experience, most recently as the Controller at Esperion Therapeutics. He joined Esperion during its early biotech stage and helped create and implement many of the financial, accounting, and operational processes that supported its transition from R&D to commercialization. Prior to Esperion, Dan worked at PwC in its assurance practice, where he earned his CPA. Dan holds a BBA and MBA from the University of Michigan.
This person is not in any teams
This person is not in any offices
Priovant
2 followers
Priovant Therapeutics is a clinical-stage biotechnology company focused on delivering novel therapies for autoimmune diseases with the heaviest patient burdens.